Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals has engaged Nordic Bioscience Clinical Development (NBCD) A/S as a complementary contract research organization to support its pivotal Phase 3 clinical trial for knee osteoarthritis. This collaboration will activate four new clinical sites in Hong Kong and Moldova, enhancing the trial’s global footprint and aligning with Hong Kong’s new ‘1+’ regulatory pathway. The strategic expansion is expected to bolster Paradigm’s commercial readiness and data robustness, with recruitment set to commence in January 2026. The initiative aims to strengthen Paradigm’s scientific and operational foundations, offering potential regulatory and commercial flexibility in the Greater Bay Area and improving data quality with diverse patient populations.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development company focused on discovering, developing, and delivering pharmaceutical therapies to improve patients’ health and quality of life. The company is currently concentrating on developing iPPS for treating diseases where inflammation plays a significant role, such as osteoarthritis.
Average Trading Volume: 1,120,886
Technical Sentiment Signal: Buy
Current Market Cap: A$150M
See more data about PAR stock on TipRanks’ Stock Analysis page.